Jake Shortt


Video presentation (1.33min) A/Prof Jake Shortt and Dr Sam Greenall talk about how they are working towards developing new therapies for haematological cancers. Published by BioCurate.

Shortt lab

Biography

Prof Jake Shortt is the Head of the Department of Haematology in the School of Clinical Sciences and Clinical Director of Monash Health Haematology. He is Principal Investigator on a range of clinical trials for T-cell lymphoma and myeloid malignancies, conducted through the Monash Haematology clinical trials unit.

Prof Shortt is the recipient of a National Health and Medical Research Council Emerging Leadership Fellowship. His translational work in the School of Clinical Sciences is focused on strategies incorporating epigenetic drugs with immunotherapy in haematological cancers, particularly lymphoma and multiple myeloma. He heads the Blood Cancer Therapeutics laboratory within the Monash Health Translation Precinct, facilitating bench-to-bedside research to progress these new treatments into the haematology clinic.

In addition to his clinical and research roles, Prof Shortt is a Board Member of the Cancer Council of Victoria and serves on the Scientific Advisory Committee of the Barrie Dalgleish Centre for Myeloma and Related Diseases.

Clinical activities

Prof Shortt attends the Monash Health myeloid disorders clinic and looks after haematology inpatients. He serves as a Principal Investigator for a range of clinical trials in leukaemia, myelodysplasia and T-cell lymphoma.

To find out more see Prof Jake Shortt's Monash profile.

Selected publications

  • Defeating MYC with drug combinations or dual-targeting drugs. Thompson PE & Shortt J. Trends Pharmacol Sci 2024; May 22:S0165-6147(24)00085-3
  • Mezigdomide in multiple myeloma. Shortt J. New Engl J Med 2023; 389: 1046-50.
  • Rationally designed chimeric PI3K-BET bromodomain inhibitors elicit curative responses in MYC-driven lymphoma. Oh DH, Ma X, Hogg SJ, He J, Kearney J, Brasacchio D, Susanto O, Maher B, Jennings IG, Newbold A, Fraser P, Gruber E, Kats LM, Gregory GP, Johnstone RW, Thompson PE, Shortt J. Proc Natl Acad Sci USA 2023; 120(36): e2306414120.
  • A phase 1 clinical trial of the repurposable acetyl-lysine mimetic, n-methyl-2-pyrrolidone (NMP), in relapsed or refractory multiple myeloma. Shortt J, Galettis P, Cheah CY, Davis J, Ludford-Menting M, Link EK, Martin JH, Koldej R, Ritchie D. Clin Epigenetics 2023; 15(1): 15.
  • Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma. Wong J, Gruber E, Maher B, Waltham M, Sabouri-Thompson Z, Jong I, Levy S, Kumar B, Brasacchio D, Jia W, So J, Skinner H, Lewis A, Hogg SJ, Vervoort S, DiCorleto C, Uhe M, Gamgee J, Opat S, Gregory GP, Polekhina G, Reynolds J, Hawkes EA, Kailainathan G, Gasiorowski R, Kats LM, Shortt J. Leukemia 2022; 36: 1654-65.
  • Plasma cell directed therapy for immune thrombotic thrombocytopenic purpura (iTTP). Chen M & Shortt J. Transfus Med Rev 2022; 36: 204-14.
  • Whole genome CRISPR screening identifies TOP2B as a potential target for IMiD sensitization in multiple myeloma. Costacurta M, Vervoort SJ, Hogg SJ, Martin BP, Johnstone RW, Shortt J. Haematologica 2021; 106: 2013-17.

Recent publications